Campo DC | Valor | Idioma |
dc.contributor.author | Parise, E. | - |
dc.contributor.author | Cheinquer, H. | - |
dc.contributor.author | Crespo, D. | - |
dc.contributor.author | Meirelles, A. | - |
dc.contributor.author | Martinelli, A. | - |
dc.contributor.author | Sette, H. | - |
dc.contributor.author | Gallizi, J. | - |
dc.contributor.author | Silva, R. | - |
dc.contributor.author | Lacet, C. | - |
dc.contributor.author | Correa, E. | - |
dc.contributor.author | Cotrim, Helma Pinchemel | - |
dc.contributor.author | Fonseca, J. | - |
dc.contributor.author | Paraná, Raymundo | - |
dc.contributor.author | Spinelli, V. | - |
dc.contributor.author | Amorim, Welma Wildes | - |
dc.contributor.author | Tatsch, Fernando | - |
dc.contributor.author | Pessoa, M. | - |
dc.creator | Parise, E. | - |
dc.creator | Cheinquer, H. | - |
dc.creator | Crespo, D. | - |
dc.creator | Meirelles, A. | - |
dc.creator | Martinelli, A. | - |
dc.creator | Sette, H. | - |
dc.creator | Gallizi, J. | - |
dc.creator | Silva, R. | - |
dc.creator | Lacet, C. | - |
dc.creator | Correa, E. | - |
dc.creator | Cotrim, Helma Pinchemel | - |
dc.creator | Fonseca, J. | - |
dc.creator | Paraná, Raymundo | - |
dc.creator | Spinelli, V. | - |
dc.creator | Amorim, Welma Wildes | - |
dc.creator | Tatsch, Fernando | - |
dc.creator | Pessoa, M. | - |
dc.date.accessioned | 2012-10-15T18:34:28Z | - |
dc.date.available | 2012-10-15T18:34:28Z | - |
dc.date.issued | 2006-02 | - |
dc.identifier.issn | 1413-8670 | - |
dc.identifier.uri | http://www.repositorio.ufba.br/ri/handle/ri/6946 | - |
dc.description | p.11-16 | pt_BR |
dc.description.abstract | Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interferon-based therapy. One-hundred-thirty-four patients with biopsy-proven chronic hepatitis C, HCV RNA positive, elevated ALT and who were either relapsers (n=37) or nonresponders (n=97) to at least 24 weeks of conventional interferon/ribavirin therapy were retreated with peginterferon alfa-2a (40KD) 180mg/qw and ribavirin 800mg bid for 48 weeks. Efficacy was assessed as virological response (defined as undetectable HCV RNA) at the end of treatment (EoT) and at the end of follow-up (SVR - Sustained Virological Response). Safety assessments consisted of clinical and laboratory evaluations. In the patient sample, 72% were genotype 1 and 34% were cirrhotic. In an intention-to-treat analysis, relapser patients showed 78% EoT response and 51% SVR. Nonresponders showed 57% EoT response and 26% SVR. Positive predictive factors of SVR were non-1 genotype and relapser state. Six percent of the patients interrupted treatment because of adverse events and 45% had dose reduction (mainly associated with leucopenia and anemia). Brazilian patient relapsers and nonresponders to conventional interferon and ribavirin treatment can achieve a sustained virological response when retreated with peginterferon alfa-2a (40KD) and ribavirin. The safety profile is similar to that of naive patients. | pt_BR |
dc.language.iso | en | pt_BR |
dc.publisher | The Brazilian Journal of Infectious Diseases and Contexto Publishing | pt_BR |
dc.source | http://dx.doi.org/10.1590/S1413-86702006000100003 | pt_BR |
dc.subject | Peginterferon alfa | pt_BR |
dc.subject | Ribavirin | pt_BR |
dc.subject | Hepatitis C | pt_BR |
dc.subject | Safety | pt_BR |
dc.subject | Efficacy | pt_BR |
dc.title | Peginterferon alfa-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy | pt_BR |
dc.title.alternative | Brazilian Journal of Infectious Diseases | pt_BR |
dc.type | Artigo de Periódico | pt_BR |
dc.description.localpub | Salvador | pt_BR |
dc.identifier.number | v. 10, n. 1 | pt_BR |
Aparece nas coleções: | Artigo Publicado em Periódico (Faculdade de Medicina)
|